Cost-effectiveness

Primary preventive screening

Knowledge resource: Health economics evaluation of primary preventive atrial fibrillation screening with thumb ECG

Tandvårds- och läkemedelsförmånsverket (The Dental and Pharmaceutical Benefits Agency) (2014)

Link to summary

Link to study (Only available in Swedish)

As part of a Government commission to evaluate medical technology, based on figures from the StrokeStop study, TLV (The Dental and Pharmaceutical Benefits Agency) has carried out a health economics assessment of primary preventive fibrillation screening. The report shows that such screening using a thumb ECG is cost-effective.


Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording

Aronsson, M., Svennberg, E., Rosenqvist, M., Endahl, J., Al-Khalili, F., Friberg, L., Frykman-Kull, V. & Levin, L-Å.

Europace. 2015. Apr 13. 1023-1029

Link to study

In a globally unique study at Karolinska Institutet, 13.000 people were offered screening for atrial fibrillation with Zenicor-ECG. Five percent of the participants were identified as new candidates for treatment with oral anticoagulants. According to this Health economical study, based on the results from the STROKESTOP study, systematic mass screening for atrial fibrillation with Zenicor-ECG is cost-effective.


Secondary preventive screening

A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke 

Levin L., Husberg M., Doliwa Sobocinski P., Frykman Kull V., Friberg L., Rosenqvist M. & Davidson T.

Europace (2014 Oct 27), Online

Link to poster

Link to study

Based on figures from the Propp-Stopp study, researchers in Linköping have been able to confirm that screening of 75-year-old stroke patients for silent atrial fibrillation is very cost-effective and after seven years, savings in terms of healthcare costs can even be seen. In the studies Zenicor-EKG has proved to be both more sensitive and result in lower costs than Holter-EKG.